<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240511222414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240511222414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 12 May 2024 02:24:15 +0000</lastbuilddate>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Redefining Iron Deficiency in Patients With Chronic Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.068883. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38733252</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068883>10.1161/CIRCULATIONAHA.124.068883</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733252</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Paul R Kalra</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Redefining Iron Deficiency in Patients With Chronic Heart Failure</dc:title>
<dc:identifier>pmid:38733252</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068883</dc:identifier>
</item>
<item>
<title>Identification of three mechanistic pathways for iron-deficient heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically with anaemia) can drive the depletion of cardiomyocyte iron, impairing contractile performance and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 11:ehae284. doi: 10.1093/eurheartj/ehae284. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically with anaemia) can drive the depletion of cardiomyocyte iron, impairing contractile performance and explaining why a transferrin saturation &lt; ≈15%-16% predicts the ability of intravenous iron to reduce the risk of major heart failure events in long-term trials (Type 1 iron-deficient heart failure). However, heart failure may be accompanied by intracellular iron depletion within skeletal muscle and cardiomyocytes, which is disproportionate to the findings of systemic iron biomarkers. Inflammation- and deconditioning-mediated skeletal muscle dysfunction-a primary cause of dyspnoea and exercise intolerance in patients with heart failure-is accompanied by intracellular skeletal myocyte iron depletion, which can be exacerbated by even mild hypoferraemia, explaining why symptoms and functional capacity improve following intravenous iron, regardless of baseline haemoglobin or changes in haemoglobin (Type 2 iron-deficient heart failure). Additionally, patients with advanced heart failure show myocardial iron depletion due to both diminished entry into and enhanced egress of iron from the myocardium; the changes in iron proteins in the cardiomyocytes of these patients are opposite to those expected from systemic iron deficiency. Nevertheless, iron supplementation can prevent ventricular remodelling and cardiomyopathy produced by experimental injury in the absence of systemic iron deficiency (Type 3 iron-deficient heart failure). These observations, taken collectively, support the possibility of three different mechanistic pathways for the development of iron-deficient heart failure: one that is driven through systemic iron depletion and impaired erythropoiesis and two that are characterized by disproportionate depletion of intracellular iron in skeletal and cardiac muscle. These mechanisms are not mutually exclusive, and all pathways may be operative at the same time or may occur sequentially in the same patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38733250</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae284>10.1093/eurheartj/ehae284</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733250</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Paul R Kalra</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Identification of three mechanistic pathways for iron-deficient heart failure</dc:title>
<dc:identifier>pmid:38733250</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae284</dc:identifier>
</item>
<item>
<title>Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 11:ehae323. doi: 10.1093/eurheartj/ehae323. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The effect of PA-guided HF therapy was evaluated in the MONITOR-HF trial among predefined subgroups based on age, sex, atrial fibrillation, diabetes mellitus, left ventricular ejection fraction, HF aetiology, cardiac resynchronisation therapy, and implantable cardioverter defibrillator. Outcome measures were based upon significance in the main trial and included quality of life, clinical, and PA pressure endpoints, and were assessed for each subgroup. Differential effects in relation to the subgroups were assessed with interaction terms. Both unadjusted and multiple testing adjusted interaction terms were presented.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The effects of PA monitoring on quality of life, clinical events, and PA pressure were consistent in the predefined subgroups, without any clinically relevant heterogeneity within or across all endpoint categories (all adjusted interaction P-values were nonsignificant). In the unadjusted analysis of the primary endpoint quality-of-life change, weak trends towards a less pronounced effect in older patients (Pinteraction = 0.03; adjusted Pinteraction = 0.33) and diabetics (Pinteraction = 0.01; adjusted Pinteraction = 0.06) were observed. However, these interaction effects did not persist after adjusting for multiple testing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38733175</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae323>10.1093/eurheartj/ehae323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733175</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>P R D Clephas</dc:creator>
<dc:creator>V W Zwartkruis</dc:creator>
<dc:creator>J Malgie</dc:creator>
<dc:creator>M W F van Gent</dc:creator>
<dc:creator>H P Brunner-La Rocca</dc:creator>
<dc:creator>M K Szymanski</dc:creator>
<dc:creator>V P van Halm</dc:creator>
<dc:creator>M L Handoko</dc:creator>
<dc:creator>W Kok</dc:creator>
<dc:creator>F W Asselbergs</dc:creator>
<dc:creator>R van Kimmenade</dc:creator>
<dc:creator>O Manintveld</dc:creator>
<dc:creator>N M D A van Mieghem</dc:creator>
<dc:creator>S L M A Beeres</dc:creator>
<dc:creator>M C Post</dc:creator>
<dc:creator>C J W Borleffs</dc:creator>
<dc:creator>R Tukkie</dc:creator>
<dc:creator>A Mosterd</dc:creator>
<dc:creator>G C M Linssen</dc:creator>
<dc:creator>R F Spee</dc:creator>
<dc:creator>M E Emans</dc:creator>
<dc:creator>T D J Smilde</dc:creator>
<dc:creator>J van Ramshorst</dc:creator>
<dc:creator>C Kirchhof</dc:creator>
<dc:creator>F Feenema-Aardema</dc:creator>
<dc:creator>C A da Fonseca</dc:creator>
<dc:creator>M van den Heuve</dc:creator>
<dc:creator>R Hazeleger</dc:creator>
<dc:creator>M van Eck</dc:creator>
<dc:creator>L van Heerebeek</dc:creator>
<dc:creator>H Boersma</dc:creator>
<dc:creator>M Rienstra</dc:creator>
<dc:creator>R A de Boer</dc:creator>
<dc:creator>J J Brugts</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial</dc:title>
<dc:identifier>pmid:38733175</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae323</dc:identifier>
</item>
<item>
<title>Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38733145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.069382. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38733145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38733145</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069382>10.1161/CIRCULATIONAHA.124.069382</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38733145</guid>
<pubDate>Sat, 11 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:creator>Meg Jardine</dc:creator>
<dc:creator>Hiddo J L Heerspink</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-05-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials</dc:title>
<dc:identifier>pmid:38733145</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069382</dc:identifier>
</item>
<item>
<title>Neurotransmitter classification from electron microscopy images at synaptic sites in Drosophila melanogaster</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38729112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>High-resolution electron microscopy of nervous systems has enabled the reconstruction of synaptic connectomes. However, we do not know the synaptic sign for each connection (i.e., whether a connection is excitatory or inhibitory), which is implied by the released transmitter. We demonstrate that artificial neural networks can predict transmitter types for presynapses from electron micrographs: a network trained to predict six transmitters (acetylcholine, glutamate, GABA, serotonin, dopamine,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9;187(10):2574-2594.e23. doi: 10.1016/j.cell.2024.03.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">High-resolution electron microscopy of nervous systems has enabled the reconstruction of synaptic connectomes. However, we do not know the synaptic sign for each connection (i.e., whether a connection is excitatory or inhibitory), which is implied by the released transmitter. We demonstrate that artificial neural networks can predict transmitter types for presynapses from electron micrographs: a network trained to predict six transmitters (acetylcholine, glutamate, GABA, serotonin, dopamine, octopamine) achieves an accuracy of 87% for individual synapses, 94% for neurons, and 91% for known cell types across a D. melanogaster whole brain. We visualize the ultrastructural features used for prediction, discovering subtle but significant differences between transmitter phenotypes. We also analyze transmitter distributions across the brain and find that neurons that develop together largely express only one fast-acting transmitter (acetylcholine, glutamate, or GABA). We hope that our publicly available predictions act as an accelerant for neuroscientific hypothesis generation for the fly.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38729112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38729112</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.016>10.1016/j.cell.2024.03.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38729112</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Nils Eckstein</dc:creator>
<dc:creator>Alexander Shakeel Bates</dc:creator>
<dc:creator>Andrew Champion</dc:creator>
<dc:creator>Michelle Du</dc:creator>
<dc:creator>Yijie Yin</dc:creator>
<dc:creator>Philipp Schlegel</dc:creator>
<dc:creator>Alicia Kun-Yang Lu</dc:creator>
<dc:creator>Thomson Rymer</dc:creator>
<dc:creator>Samantha Finley-May</dc:creator>
<dc:creator>Tyler Paterson</dc:creator>
<dc:creator>Ruchi Parekh</dc:creator>
<dc:creator>Sven Dorkenwald</dc:creator>
<dc:creator>Arie Matsliah</dc:creator>
<dc:creator>Szi-Chieh Yu</dc:creator>
<dc:creator>Claire McKellar</dc:creator>
<dc:creator>Amy Sterling</dc:creator>
<dc:creator>Katharina Eichler</dc:creator>
<dc:creator>Marta Costa</dc:creator>
<dc:creator>Sebastian Seung</dc:creator>
<dc:creator>Mala Murthy</dc:creator>
<dc:creator>Volker Hartenstein</dc:creator>
<dc:creator>Gregory S X E Jefferis</dc:creator>
<dc:creator>Jan Funke</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Neurotransmitter classification from electron microscopy images at synaptic sites in Drosophila melanogaster</dc:title>
<dc:identifier>pmid:38729112</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.016</dc:identifier>
</item>
<item>
<title>The phosphorylation landscape of infection-related development by the rice blast fungus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38729111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>Many of the world's most devastating crop diseases are caused by fungal pathogens that elaborate specialized infection structures to invade plant tissue. Here, we present a quantitative mass-spectrometry-based phosphoproteomic analysis of infection-related development by the rice blast fungus Magnaporthe oryzae, which threatens global food security. We mapped 8,005 phosphosites on 2,062 fungal proteins following germination on a hydrophobic surface, revealing major re-wiring of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9;187(10):2557-2573.e18. doi: 10.1016/j.cell.2024.04.007.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many of the world's most devastating crop diseases are caused by fungal pathogens that elaborate specialized infection structures to invade plant tissue. Here, we present a quantitative mass-spectrometry-based phosphoproteomic analysis of infection-related development by the rice blast fungus Magnaporthe oryzae, which threatens global food security. We mapped 8,005 phosphosites on 2,062 fungal proteins following germination on a hydrophobic surface, revealing major re-wiring of phosphorylation-based signaling cascades during appressorium development. Comparing phosphosite conservation across 41 fungal species reveals phosphorylation signatures specifically associated with biotrophic and hemibiotrophic fungal infection. We then used parallel reaction monitoring (PRM) to identify phosphoproteins regulated by the fungal Pmk1 MAPK that controls plant infection by M. oryzae. We define 32 substrates of Pmk1 and show that Pmk1-dependent phosphorylation of regulator Vts1 is required for rice blast disease. Defining the phosphorylation landscape of infection therefore identifies potential therapeutic interventions for the control of plant diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38729111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38729111</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.007>10.1016/j.cell.2024.04.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38729111</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Neftaly Cruz-Mireles</dc:creator>
<dc:creator>Miriam Osés-Ruiz</dc:creator>
<dc:creator>Paul Derbyshire</dc:creator>
<dc:creator>Clara Jégousse</dc:creator>
<dc:creator>Lauren S Ryder</dc:creator>
<dc:creator>Mark Jave A Bautista</dc:creator>
<dc:creator>Alice Eseola</dc:creator>
<dc:creator>Jan Sklenar</dc:creator>
<dc:creator>Bozeng Tang</dc:creator>
<dc:creator>Xia Yan</dc:creator>
<dc:creator>Weibin Ma</dc:creator>
<dc:creator>Kim C Findlay</dc:creator>
<dc:creator>Vincent Were</dc:creator>
<dc:creator>Dan MacLean</dc:creator>
<dc:creator>Nicholas J Talbot</dc:creator>
<dc:creator>Frank L H Menke</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The phosphorylation landscape of infection-related development by the rice blast fungus</dc:title>
<dc:identifier>pmid:38729111</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.007</dc:identifier>
</item>
<item>
<title>Analysis of 3D pathology samples using weakly supervised AI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38729110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>Human tissue, which is inherently three-dimensional (3D), is traditionally examined through standard-of-care histopathology as limited two-dimensional (2D) cross-sections that can insufficiently represent the tissue due to sampling bias. To holistically characterize histomorphology, 3D imaging modalities have been developed, but clinical translation is hampered by complex manual evaluation and lack of computational platforms to distill clinical insights from large, high-resolution datasets. We...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9;187(10):2502-2520.e17. doi: 10.1016/j.cell.2024.03.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human tissue, which is inherently three-dimensional (3D), is traditionally examined through standard-of-care histopathology as limited two-dimensional (2D) cross-sections that can insufficiently represent the tissue due to sampling bias. To holistically characterize histomorphology, 3D imaging modalities have been developed, but clinical translation is hampered by complex manual evaluation and lack of computational platforms to distill clinical insights from large, high-resolution datasets. We present TriPath, a deep-learning platform for processing tissue volumes and efficiently predicting clinical outcomes based on 3D morphological features. Recurrence risk-stratification models were trained on prostate cancer specimens imaged with open-top light-sheet microscopy or microcomputed tomography. By comprehensively capturing 3D morphologies, 3D volume-based prognostication achieves superior performance to traditional 2D slice-based approaches, including clinical/histopathological baselines from six certified genitourinary pathologists. Incorporating greater tissue volume improves prognostic performance and mitigates risk prediction variability from sampling bias, further emphasizing the value of capturing larger extents of heterogeneous morphology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38729110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38729110</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.035>10.1016/j.cell.2024.03.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38729110</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrew H Song</dc:creator>
<dc:creator>Mane Williams</dc:creator>
<dc:creator>Drew F K Williamson</dc:creator>
<dc:creator>Sarah S L Chow</dc:creator>
<dc:creator>Guillaume Jaume</dc:creator>
<dc:creator>Gan Gao</dc:creator>
<dc:creator>Andrew Zhang</dc:creator>
<dc:creator>Bowen Chen</dc:creator>
<dc:creator>Alexander S Baras</dc:creator>
<dc:creator>Robert Serafin</dc:creator>
<dc:creator>Richard Colling</dc:creator>
<dc:creator>Michelle R Downes</dc:creator>
<dc:creator>Xavier Farré</dc:creator>
<dc:creator>Peter Humphrey</dc:creator>
<dc:creator>Clare Verrill</dc:creator>
<dc:creator>Lawrence D True</dc:creator>
<dc:creator>Anil V Parwani</dc:creator>
<dc:creator>Jonathan T C Liu</dc:creator>
<dc:creator>Faisal Mahmood</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Analysis of 3D pathology samples using weakly supervised AI</dc:title>
<dc:identifier>pmid:38729110</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.035</dc:identifier>
</item>
<item>
<title>The future of rapid and automated single-cell data analysis using reference mapping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38729109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>As the number of single-cell datasets continues to grow rapidly, workflows that map new data to well-curated reference atlases offer enormous promise for the biological community. In this perspective, we discuss key computational challenges and opportunities for single-cell reference-mapping algorithms. We discuss how mapping algorithms will enable the integration of diverse datasets across disease states, molecular modalities, genetic perturbations, and diverse species and will eventually...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9;187(10):2343-2358. doi: 10.1016/j.cell.2024.03.009.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">As the number of single-cell datasets continues to grow rapidly, workflows that map new data to well-curated reference atlases offer enormous promise for the biological community. In this perspective, we discuss key computational challenges and opportunities for single-cell reference-mapping algorithms. We discuss how mapping algorithms will enable the integration of diverse datasets across disease states, molecular modalities, genetic perturbations, and diverse species and will eventually replace manual and laborious unsupervised clustering pipelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38729109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38729109</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.009>10.1016/j.cell.2024.03.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38729109</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mohammad Lotfollahi</dc:creator>
<dc:creator>None Yuhan Hao</dc:creator>
<dc:creator>Fabian J Theis</dc:creator>
<dc:creator>Rahul Satija</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The future of rapid and automated single-cell data analysis using reference mapping</dc:title>
<dc:identifier>pmid:38729109</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.009</dc:identifier>
</item>
<item>
<title>Correction to: Tackling cardiovascular healthcare disparities for the LGBTQIA+ population: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38728114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 10:ehae269. doi: 10.1093/eurheartj/ehae269. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38728114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38728114</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae269>10.1093/eurheartj/ehae269</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38728114</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Tackling cardiovascular healthcare disparities for the LGBTQIA+ population: a call to action</dc:title>
<dc:identifier>pmid:38728114</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae269</dc:identifier>
</item>
<item>
<title>2024 Hypertrophic Cardiomyopathy Guideline-at-a-Glance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38727648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 3:S0735-1097(24)06825-6. doi: 10.1016/j.jacc.2024.04.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38727648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38727648</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.002>10.1016/j.jacc.2024.04.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38727648</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan Coylewright</dc:creator>
<dc:creator>Morgane Cibotti-Sun</dc:creator>
<dc:creator>Mykela M Moore</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 Hypertrophic Cardiomyopathy Guideline-at-a-Glance</dc:title>
<dc:identifier>pmid:38727648</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.002</dc:identifier>
</item>
<item>
<title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38727647/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 3:S0735-1097(24)00382-6. doi: 10.1016/j.jacc.2024.02.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38727647/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38727647</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.014>10.1016/j.jacc.2024.02.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38727647</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Writing Committee Members</dc:creator>
<dc:creator>Steve R Ommen</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Irfan M Asif</dc:creator>
<dc:creator>Seshadri Balaji</dc:creator>
<dc:creator>Michael A Burke</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Joseph A Dearani</dc:creator>
<dc:creator>Kelly C Epps</dc:creator>
<dc:creator>Lauren Evanovich</dc:creator>
<dc:creator>Victor A Ferrari</dc:creator>
<dc:creator>José A Joglar</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Jeffrey J Kim</dc:creator>
<dc:creator>Michelle M Kittleson</dc:creator>
<dc:creator>Chayakrit Krittanawong</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Seema Mital</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Sabrina Times</dc:creator>
<dc:creator>Cynthia Burstein Waldman</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38727647</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.014</dc:identifier>
</item>
<item>
<title>Left atrial intramural haematoma mimicking a thrombus traversing the interatrial septum following thrombolytic therapy for pulmonary embolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38727577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 10:ehae232. doi: 10.1093/eurheartj/ehae232. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38727577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38727577</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae232>10.1093/eurheartj/ehae232</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38727577</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Takumi Osawa</dc:creator>
<dc:creator>Yoshihide Tanabe</dc:creator>
<dc:creator>Hidetaka Nishina</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial intramural haematoma mimicking a thrombus traversing the interatrial septum following thrombolytic therapy for pulmonary embolism</dc:title>
<dc:identifier>pmid:38727577</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae232</dc:identifier>
</item>
<item>
<title>Spexin Diminishes Atrial Fibrillation Vulnerability by Acting on Galanin Receptor 2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38726666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Spexin reduces atrial fibrillation susceptibility by inhibiting CREB phosphorylation and thus downregulating KCNJ2 and SLN transcription by GALR2 receptor. The spexin/GALR2/CREB signaling pathway represents a novel therapeutic avenue in the development of agents against atrial fibrillation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 10. doi: 10.1161/CIRCULATIONAHA.123.067517. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: G protein-coupled receptors play a critical role in atrial fibrillation (AF). Spexin is a novel ligand of galanin receptors (GALRs). In this study, we investigated the regulation of spexin and GALRs on AF and the underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Global spexin knockout (SPX-KO) and cardiomyocyte-specific GALRs knockout (GALR-cKO) mice underwent burst pacing electrical stimulation. Optical mapping was used to determine atrial conduction velocity and action potential duration. Atrial myocyte action potential duration and inward rectifying K<sup>+</sup> current (<i>I</i><sub>K1</sub>) were recorded using whole-cell patch clamps. Isolated cardiomyocytes were stained with Fluo-3/AM dye, and intracellular Ca<sup>2+</sup> handling was examined by CCD camera. A mouse model of AF was established by Ang-II (angiotensin II) infusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Spexin plasma levels in patients with AF were lower than those in subjects without AF, and knockout of spexin increased AF susceptibility in mice. In the atrium of SPX-KO mice, potassium inwardly rectifying channel subfamily J member 2 (KCNJ2) and sarcolipin (SLN) were upregulated; meanwhile, <i>I</i><sub>K1</sub> current was increased and Ca<sup>2+</sup> handling was impaired in isolated atrial myocytes of SPX-KO mice. GALR2-cKO mice, but not GALR1-cKO and GALR3-cKO mice, had a higher incidence of AF, which was associated with higher <i>I</i><sub>K1</sub> current and intracellular Ca<sup>2+</sup> overload. The phosphorylation level of CREB (cyclic AMP responsive element binding protein 1) was upregulated in atrial tissues of SPX-KO and GALR2-cKO mice. Chromatin immunoprecipitation confirmed the recruitment of p-CREB to the proximal promoter regions of KCNJ2 and SLN. Finally, spexin treatment suppressed CREB signaling, decreased <i>I</i><sub>K1</sub> current and intracellular Ca<sup>2+</sup> overload, which thus reduced the inducibility of AF in Ang-II-infused mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Spexin reduces atrial fibrillation susceptibility by inhibiting CREB phosphorylation and thus downregulating KCNJ2 and SLN transcription by GALR2 receptor. The spexin/GALR2/CREB signaling pathway represents a novel therapeutic avenue in the development of agents against atrial fibrillation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38726666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38726666</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067517>10.1161/CIRCULATIONAHA.123.067517</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38726666</guid>
<pubDate>Fri, 10 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Desheng Li</dc:creator>
<dc:creator>Yang Liu</dc:creator>
<dc:creator>Changzhu Li</dc:creator>
<dc:creator>Zhiwen Zhou</dc:creator>
<dc:creator>Kangyi Gao</dc:creator>
<dc:creator>Hairong Ba</dc:creator>
<dc:creator>Jiming Yang</dc:creator>
<dc:creator>Genlong Xue</dc:creator>
<dc:creator>Dechun Yin</dc:creator>
<dc:creator>Xinbo Zhao</dc:creator>
<dc:creator>Kewei Shen</dc:creator>
<dc:creator>Lingmin Zhang</dc:creator>
<dc:creator>Jialiang Li</dc:creator>
<dc:creator>Chenhong Li</dc:creator>
<dc:creator>Jiahui Song</dc:creator>
<dc:creator>Lexin Zhao</dc:creator>
<dc:creator>Yao Pei</dc:creator>
<dc:creator>Lina Xuan</dc:creator>
<dc:creator>Yang Zhang</dc:creator>
<dc:creator>Yanjie Lu</dc:creator>
<dc:creator>Zhi-Ren Zhang</dc:creator>
<dc:creator>Baofeng Yang</dc:creator>
<dc:creator>Yue Li</dc:creator>
<dc:creator>Zhenwei Pan</dc:creator>
<dc:date>2024-05-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Spexin Diminishes Atrial Fibrillation Vulnerability by Acting on Galanin Receptor 2</dc:title>
<dc:identifier>pmid:38726666</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067517</dc:identifier>
</item>
<item>
<title>Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723628/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>Hepatitis B virus (HBV) is a small double-stranded DNA virus that chronically infects 296 million people. Over half of its compact genome encodes proteins in two overlapping reading frames, and during evolution, multiple selective pressures can act on shared nucleotides. This study combines an RNA-based HBV cell culture system with deep mutational scanning (DMS) to uncouple cis- and trans-acting sequence requirements in the HBV genome. The results support a leaky ribosome scanning model for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 2:S0092-8674(24)00403-3. doi: 10.1016/j.cell.2024.04.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hepatitis B virus (HBV) is a small double-stranded DNA virus that chronically infects 296 million people. Over half of its compact genome encodes proteins in two overlapping reading frames, and during evolution, multiple selective pressures can act on shared nucleotides. This study combines an RNA-based HBV cell culture system with deep mutational scanning (DMS) to uncouple cis- and trans-acting sequence requirements in the HBV genome. The results support a leaky ribosome scanning model for polymerase translation, provide a fitness map of the HBV polymerase at single-nucleotide resolution, and identify conserved prolines adjacent to the HBV polymerase termination codon that stall ribosomes. Further experiments indicated that stalled ribosomes tether the nascent polymerase to its template RNA, ensuring cis-preferential RNA packaging and reverse transcription of the HBV genome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723628/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723628</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.008>10.1016/j.cell.2024.04.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723628</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yingpu Yu</dc:creator>
<dc:creator>Maximilian A Kass</dc:creator>
<dc:creator>Mengyin Zhang</dc:creator>
<dc:creator>Noor Youssef</dc:creator>
<dc:creator>Catherine A Freije</dc:creator>
<dc:creator>Kelly P Brock</dc:creator>
<dc:creator>Lauren C Aguado</dc:creator>
<dc:creator>Leon L Seifert</dc:creator>
<dc:creator>Sanjana Venkittu</dc:creator>
<dc:creator>Xupeng Hong</dc:creator>
<dc:creator>Amir Shlomai</dc:creator>
<dc:creator>Ype P de Jong</dc:creator>
<dc:creator>Debora S Marks</dc:creator>
<dc:creator>Charles M Rice</dc:creator>
<dc:creator>William M Schneider</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Deep mutational scanning of hepatitis B virus reveals a mechanism for cis-preferential reverse transcription</dc:title>
<dc:identifier>pmid:38723628</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.008</dc:identifier>
</item>
<item>
<title>Circadian tumor infiltration and function of CD8&lt;sup>;+&lt;/sup>; T cells dictate immunotherapy efficacy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>The quality and quantity of tumor-infiltrating lymphocytes, particularly CD8^(+) T cells, are important parameters for the control of tumor growth and response to immunotherapy. Here, we show in murine and human cancers that these parameters exhibit circadian oscillations, driven by both the endogenous circadian clock of leukocytes and rhythmic leukocyte infiltration, which depends on the circadian clock of endothelial cells in the tumor microenvironment. To harness these rhythms...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 2:S0092-8674(24)00410-0. doi: 10.1016/j.cell.2024.04.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The quality and quantity of tumor-infiltrating lymphocytes, particularly CD8<sup>+</sup> T cells, are important parameters for the control of tumor growth and response to immunotherapy. Here, we show in murine and human cancers that these parameters exhibit circadian oscillations, driven by both the endogenous circadian clock of leukocytes and rhythmic leukocyte infiltration, which depends on the circadian clock of endothelial cells in the tumor microenvironment. To harness these rhythms therapeutically, we demonstrate that efficacy of chimeric antigen receptor T cell therapy and immune checkpoint blockade can be improved by adjusting the time of treatment during the day. Furthermore, time-of-day-dependent T cell signatures in murine tumor models predict overall survival in patients with melanoma and correlate with response to anti-PD-1 therapy. Our data demonstrate the functional significance of circadian dynamics in the tumor microenvironment and suggest the importance of leveraging these features for improving future clinical trial design and patient care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723627</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.015>10.1016/j.cell.2024.04.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723627</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Chen Wang</dc:creator>
<dc:creator>Qun Zeng</dc:creator>
<dc:creator>Zeynep Melis Gül</dc:creator>
<dc:creator>Sisi Wang</dc:creator>
<dc:creator>Robert Pick</dc:creator>
<dc:creator>Phil Cheng</dc:creator>
<dc:creator>Ruben Bill</dc:creator>
<dc:creator>Yan Wu</dc:creator>
<dc:creator>Stefan Naulaerts</dc:creator>
<dc:creator>Coline Barnoud</dc:creator>
<dc:creator>Pei-Chun Hsueh</dc:creator>
<dc:creator>Sofie Hedlund Moller</dc:creator>
<dc:creator>Mara Cenerenti</dc:creator>
<dc:creator>Mengzhu Sun</dc:creator>
<dc:creator>Ziyang Su</dc:creator>
<dc:creator>Stéphane Jemelin</dc:creator>
<dc:creator>Volodymyr Petrenko</dc:creator>
<dc:creator>Charna Dibner</dc:creator>
<dc:creator>Stéphanie Hugues</dc:creator>
<dc:creator>Camilla Jandus</dc:creator>
<dc:creator>Zhongwu Li</dc:creator>
<dc:creator>Olivier Michielin</dc:creator>
<dc:creator>Ping-Chih Ho</dc:creator>
<dc:creator>Abhishek D Garg</dc:creator>
<dc:creator>Federico Simonetta</dc:creator>
<dc:creator>Mikaël J Pittet</dc:creator>
<dc:creator>Christoph Scheiermann</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Circadian tumor infiltration and function of CD8&lt;sup>;+&lt;/sup>; T cells dictate immunotherapy efficacy</dc:title>
<dc:identifier>pmid:38723627</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.015</dc:identifier>
</item>
<item>
<title>Circadian-Regulated GR Signaling Mediates Morning Arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1327-1329. doi: 10.1161/CIRCRESAHA.124.324571. Epub 2024 May 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723035</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324571>10.1161/CIRCRESAHA.124.324571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723035</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Inna Rabinovich-Nikitin</dc:creator>
<dc:creator>Molly Crandall</dc:creator>
<dc:creator>Lorrie A Kirshenbaum</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Circadian-Regulated GR Signaling Mediates Morning Arrhythmias</dc:title>
<dc:identifier>pmid:38723035</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324571</dc:identifier>
</item>
<item>
<title>Keeps Cardiac Pericytes in Good Shape: Regulator of G-Protein Signaling-5</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723034/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1256-1258. doi: 10.1161/CIRCRESAHA.124.324476. Epub 2024 May 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723034/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723034</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324476>10.1161/CIRCRESAHA.124.324476</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723034</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Michaela Kuhn</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Keeps Cardiac Pericytes in Good Shape: Regulator of G-Protein Signaling-5</dc:title>
<dc:identifier>pmid:38723034</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324476</dc:identifier>
</item>
<item>
<title>Pacemaker Channels and the Chronotropic Response in Health and Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723033/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>Loss or dysregulation of the normally precise control of heart rate via the autonomic nervous system plays a critical role during the development and progression of cardiovascular disease-including ischemic heart disease, heart failure, and arrhythmias. While the clinical significance of regulating changes in heart rate, known as the chronotropic effect, is undeniable, the mechanisms controlling these changes remain not fully understood. Heart rate acceleration and deceleration are mediated by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1348-1378. doi: 10.1161/CIRCRESAHA.123.323250. Epub 2024 May 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Loss or dysregulation of the normally precise control of heart rate via the autonomic nervous system plays a critical role during the development and progression of cardiovascular disease-including ischemic heart disease, heart failure, and arrhythmias. While the clinical significance of regulating changes in heart rate, known as the chronotropic effect, is undeniable, the mechanisms controlling these changes remain not fully understood. Heart rate acceleration and deceleration are mediated by increasing or decreasing the spontaneous firing rate of pacemaker cells in the sinoatrial node. During the transition from rest to activity, sympathetic neurons stimulate these cells by activating β-adrenergic receptors and increasing intracellular cyclic adenosine monophosphate. The same signal transduction pathway is targeted by positive chronotropic drugs such as norepinephrine and dobutamine, which are used in the treatment of cardiogenic shock and severe heart failure. The cyclic adenosine monophosphate-sensitive hyperpolarization-activated current (I<sub>f</sub>) in pacemaker cells is passed by hyperpolarization-activated cyclic nucleotide-gated cation channels and is critical for generating the autonomous heartbeat. In addition, this current has been suggested to play a central role in the chronotropic effect. Recent studies demonstrate that cyclic adenosine monophosphate-dependent regulation of HCN4 (hyperpolarization-activated cyclic nucleotide-gated cation channel isoform 4) acts to stabilize the heart rate, particularly during rapid rate transitions induced by the autonomic nervous system. The mechanism is based on creating a balance between firing and recently discovered nonfiring pacemaker cells in the sinoatrial node. In this way, hyperpolarization-activated cyclic nucleotide-gated cation channels may protect the heart from sinoatrial node dysfunction, secondary arrhythmia of the atria, and potentially fatal tachyarrhythmia of the ventricles. Here, we review the latest findings on sinoatrial node automaticity and discuss the physiological and pathophysiological role of HCN pacemaker channels in the chronotropic response and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723033/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723033</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11081487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">PMC11081487</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323250>10.1161/CIRCRESAHA.123.323250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723033</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Konstantin Hennis</dc:creator>
<dc:creator>Chiara Piantoni</dc:creator>
<dc:creator>Martin Biel</dc:creator>
<dc:creator>Stefanie Fenske</dc:creator>
<dc:creator>Christian Wahl-Schott</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Pacemaker Channels and the Chronotropic Response in Health and Disease</dc:title>
<dc:identifier>pmid:38723033</dc:identifier>
<dc:identifier>pmc:PMC11081487</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323250</dc:identifier>
</item>
<item>
<title>Arrhythmogenic Manifestations of Chagas Disease: Perspectives From the Bench to Bedside</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723031/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>Chagas cardiomyopathy caused by infection with the intracellular parasite Trypanosoma cruzi is the most common and severe expression of human Chagas disease. Heart failure, systemic and pulmonary thromboembolism, arrhythmia, and sudden cardiac death are the principal clinical manifestations of Chagas cardiomyopathy. Ventricular arrhythmias contribute significantly to morbidity and mortality and are the major cause of sudden cardiac death. Significant gaps still exist in the understanding of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1379-1397. doi: 10.1161/CIRCRESAHA.124.324507. Epub 2024 May 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chagas cardiomyopathy caused by infection with the intracellular parasite <i>Trypanosoma cruzi</i> is the most common and severe expression of human Chagas disease. Heart failure, systemic and pulmonary thromboembolism, arrhythmia, and sudden cardiac death are the principal clinical manifestations of Chagas cardiomyopathy. Ventricular arrhythmias contribute significantly to morbidity and mortality and are the major cause of sudden cardiac death. Significant gaps still exist in the understanding of the pathogenesis mechanisms underlying the arrhythmogenic manifestations of Chagas cardiomyopathy. This article will review the data from experimental studies and translate those findings to draw hypotheses about clinical observations. Human- and animal-based studies at molecular, cellular, tissue, and organ levels suggest 5 main pillars of remodeling caused by the interaction of host and parasite: immunologic, electrical, autonomic, microvascular, and contractile. Integrating these 5 remodeling processes will bring insights into the current knowledge in the field, highlighting some key features for future management of this arrhythmogenic disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723031/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723031</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11081486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">PMC11081486</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324507>10.1161/CIRCRESAHA.124.324507</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723031</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Danilo Roman-Campos</dc:creator>
<dc:creator>José Antonio Marin-Neto</dc:creator>
<dc:creator>Artur Santos-Miranda</dc:creator>
<dc:creator>Nathan Kong</dc:creator>
<dc:creator>André D'Avila</dc:creator>
<dc:creator>Anis Rassi</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Arrhythmogenic Manifestations of Chagas Disease: Perspectives From the Bench to Bedside</dc:title>
<dc:identifier>pmid:38723031</dc:identifier>
<dc:identifier>pmc:PMC11081486</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324507</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723030/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1232-1233. doi: 10.1161/RES.0000000000000672. Epub 2024 May 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723030/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723030</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000672>10.1161/RES.0000000000000672</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723030</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38723030</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000672</dc:identifier>
</item>
<item>
<title>Salt Sensitivity of Blood Pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38723029/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240511222414&amp;v=2.18.0.post9+e462414
      <description>The year 2024 marks the centennial of the initiation of the American Heart Association. Over the past 100 years, the American Heart Association has led groundbreaking discoveries in cardiovascular disease including salt sensitivity of blood pressure, which has been studied since the mid-1900s. Salt sensitivity of blood pressure is an important risk factor for cardiovascular events, but the phenotype remains unclear because of insufficient understanding of the underlying mechanisms and lack of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 10;134(10):1234-1239. doi: 10.1161/CIRCRESAHA.123.322982. Epub 2024 May 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The year 2024 marks the centennial of the initiation of the American Heart Association. Over the past 100 years, the American Heart Association has led groundbreaking discoveries in cardiovascular disease including salt sensitivity of blood pressure, which has been studied since the mid-1900s. Salt sensitivity of blood pressure is an important risk factor for cardiovascular events, but the phenotype remains unclear because of insufficient understanding of the underlying mechanisms and lack of feasible diagnostic tools. In honor of this centennial, we commemorate the initial discovery of salt sensitivity of blood pressure and chronicle the subsequent scientific discoveries and efforts to mitigate salt-induced cardiovascular disease with American Heart Association leading the way. We also highlight determinants of the pathophysiology of salt sensitivity of blood pressure in humans and recent developments in diagnostic methods and future prospects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38723029/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240511222414&v=2.18.0.post9+e462414">38723029</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322982>10.1161/CIRCRESAHA.123.322982</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38723029</guid>
<pubDate>Thu, 09 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeremiah Afolabi</dc:creator>
<dc:creator>Cheryl L Laffer</dc:creator>
<dc:creator>Heather K Beasley</dc:creator>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Sepiso K Masenga</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2024-05-09</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt Sensitivity of Blood Pressure</dc:title>
<dc:identifier>pmid:38723029</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322982</dc:identifier>
</item>





























</channel>
</rss>